Expand STOK Menu
STOK MENU

STOK Latest Press Releases

-- April 16, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- April 8, 2026 --

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference Business Wire 4:01 PM
The Credibility Filter Wall Street Uses to Sort Biotech Winners Globe Newswire 9:15 AM

-- April 7, 2026 --

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors Business Wire 4:01 PM

-- March 17, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 5:12 PM

-- March 4, 2026 --

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome Business Wire 5:06 PM
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome Globe Newswire 5:05 PM

-- February 24, 2026 --

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference Business Wire 4:01 PM

-- February 18, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- February 11, 2026 --

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) Business Wire 7:30 AM

-- February 4, 2026 --

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Business Wire 4:01 PM

-- January 27, 2026 --

Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA PRNewswire 2:06 PM

-- January 16, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- January 11, 2026 --

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome Business Wire 2:00 PM

-- January 6, 2026 --

Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire 4:01 PM

-- December 16, 2025 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- December 5, 2025 --

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting Business Wire 9:00 AM
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting Globe Newswire 9:00 AM

-- December 1, 2025 --

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting Globe Newswire 7:30 AM
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting Business Wire 7:30 AM
Market Data Delayed 15 Minutes